. Author manuscript; available in PMC: 2020 Sep 3.

Published in final edited form as: J Neurosurg. 2018 Dec 1;129(6):1397–1406. doi: 10.3171/2017.7.JNS171286

TABLE 3.

Tumor response categorization at time points following SRS

Time Since SRS	No Ipilimumab			Concurrent Ipilimumab			Nonconcurrent Ipilimumab			p Value
	Resp^*	Stab^†	Prog^‡	Resp^*	Stab^†	Prog^‡	Resp^*	Stab^†	Prog^‡
	1.5 mos	45 (69%)	12 (18%)	8 (12%)	34 (62%)	14 (25%)	7 (13%)	94 (70%)	28 (21%)		13 (10%)	0.82

3 mos	30 (73%)	4 (10%)	7 (17%)	42 (89%)	5 (11%)	0 (0%)	54 (63%)	15 (17%)	17 (20%)	0.002

6 mos	20 (56%)	2 (5%)	14 (39%)	33 (77%)	9 (21%)	1 (2%)	59 (67%)	7 (8%)	22 (25%)	<0.001

Prog = progression; resp = response; stab = stable.

Values are shown as the number of lesions (%) unless otherwise indicated.

> 30% tumor volume reduction.

^†

Neither > 30% tumor volume reduction nor increase.

^‡

> 30% tumor volume increase.